FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROVAL						
OMB Number:	3235-0287					
Estimated average but	rden					
hours per response	0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses)													
Name and Address of Reporting Person * Matthews Judith M.				2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]					5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.			C, BLK	3. Date of Earliest Transaction (Month/Day/Year) 03/11/2021						X Officer (give title below) Other (specify below) Chief Financial Officer			w)	
DUBLIN, L2 2				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing/Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu						ured, Disposed of, or Beneficially Owned				
1.Title of Sec (Instr. 3)	curity			2A. Deen Execution any (Month/E	Date, if	(Instr. 8) (A	Securities Acc) or Disposed (str. 3, 4 and 5 (A) or (D)	of (D) Ov Tr (Ir	Amount of S wned Followi ransaction(s) nstr. 3 and 4)		1		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			liass of securities of	chenciany	owned di	rectly or	indirectly.	•	.14.46		<u> </u>		. J. GEG	1474 (0.02)
			Table II -	Derivativ	e Securiti	ies Acqu	Persons in this for displays	who respor orm are not it a currently sed of, or Ben	equired to valid OM	to respond B control n	unless the		ed SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Table II -	Derivative (e.g., puts.) 4. Transact Code	5. Nu Securiti (calls, wa 5. Nu Deriv Security Acquor Di (D)	ies Acquarrants, umber of vative rities uired (A) sposed of co. 3, 4,	Persons in this f displays ired, Dispo options, cor 6. Date E and Expi (Month/I	orm are not in a currently sed of, or Ben exercisable atton Date	equired t valid OM eficially O	to respond B control n wned and Amount ying	unless the umber. 8. Price of		f 10. Owners Form of Derivati Security Direct (or Indire	11. Natur of Indirec Beneficia Ownershi : (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - (3A. Deemed Execution Date, if	Derivative (e.g., puts.) 4. Transact Code	5. Nuion Derivi Secu Acquior Di (D) (Instr	dies Acquarrants, under of vative rities dired (A) sposed of (A) (A) (B) (A) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B	Persons in this for displays ired, Dispo options, con 6. Date E and Expi (Month/I f	orm are not it a currently seed of, or Ben vertible security secur	required to valid OM/ eficially Orities) 7. Title an of Underly Securities	to respond B control n wned and Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Owners Form of Derivati Security Direct (or Indire	11. Natur of Indirec Beneficia Ownershi (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Matthews Judith M. C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2			Chief Financial Officer		

Signatures

/s/ Judith M. Matthews	03/15/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.
- (2) Subject to the reporting person providing continuous service to the Issuer on the relevant vesting date and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest 50% on March 11, 2022 and 50% on March 11, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.